KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$8.0 million.

  • Recursion Pharmaceuticals' Change in Accured Expenses fell 22652.39% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.7 million, marking a year-over-year decrease of 47376.01%. This contributed to the annual value of $5.5 million for FY2024, which is 1785.98% down from last year.
  • Recursion Pharmaceuticals' Change in Accured Expenses amounted to -$8.0 million in Q3 2025, which was down 22652.39% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Accured Expenses peaked at $12.2 million during Q4 2022, and registered a low of -$26.6 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.1 million (2022), whereas its average is $62105.3.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 115632.75% in 2021, then plummeted by 1168000.0% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $1.6 million in 2021, then skyrocketed by 641.26% to $12.2 million in 2022, then crashed by 77.12% to $2.8 million in 2023, then surged by 278.01% to $10.5 million in 2024, then crashed by 176.36% to -$8.0 million in 2025.
  • Its Change in Accured Expenses was -$8.0 million in Q3 2025, compared to $11.4 million in Q2 2025 and -$26.6 million in Q1 2025.